)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
CeriBell
CeriBell (CBLL) investor relations material
CeriBell Canaccord Genuity's 46th Annual Growth Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Canaccord Genuity's 46th Annual Growth Conference summary12 Aug, 2026
Technology and product innovation
Developed rapid EEG brainwave monitoring with AI-powered algorithms for acute care, enabling real-time detection of neurological conditions in emergency and ICU settings.
Technology is easy to set up, typically by nurses in about five minutes, overcoming traditional EEG bottlenecks.
Over 150 publications and abstracts support improved clinical outcomes, reduced medication overuse, and shorter hospital stays.
New hardware platform announced, supporting seizure, delirium, and future stroke detection, with FDA breakthrough designation for stroke.
Two new disposables and a recorder platform with integrated video and EKG capabilities are being introduced, enhancing monitoring and user experience.
Market expansion and commercial strategy
Currently in 712 U.S. hospitals, targeting seizure detection as the first phase, with plans to become a comprehensive brain monitor and vital sign in acute care.
U.S. total addressable market (TAM) expanded from $2 billion to over $3.5 billion by adding neonate, pediatric, and delirium indications.
Sales force expanded post-IPO from 35 to 55 territory managers, with productivity ramping up over a two-year cycle.
Strategic account managers now focus on multi-hospital regional health systems, building a pipeline of larger deals expected to impact results by 2027.
Utilization per account has increased significantly, with top hospitals using the technology at three times the average rate, indicating further growth potential.
Financials, reimbursement, and operating leverage
Received favorable CMS reimbursement for delirium, adding over $2,000 per eligible patient, aiding hospital adoption.
NTAP reimbursement viewed as an objection handler for hospitals rather than a primary usage driver; transition from status epilepticus to delirium reimbursement expected to be neutral.
Adjusted EBITDA has remained consistent, with ongoing investment in sales and product development aimed at long-term growth and market impact.
Focus remains on maximizing market impact and long-term revenue rather than short-term operating leverage.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from CeriBell
- AI-powered EEG platform accelerates acute care diagnosis, fueling rapid growth and market expansion.CBLL
Corporate presentation - Q2 2026 revenue up 33% to $28.1M, gross margin 92%, new credit facility and guidance raised.CBLLQ2 2026
- Rapidly growing EEG platform achieves strong margins and expands US hospital adoption.CBLLCG MedTech, Diagnostics and Digital Health & Services Forum
- AI-driven EEG platform accelerates acute seizure diagnosis, fueling rapid growth and market expansion.CBLLCorporate presentation
- Rapid EEG platform with AI expands into new markets, driving strong growth and clinical adoption.CBLL46th Annual William Blair Growth Stock Conference
- Directors were re-elected and the auditor ratified, with all proposals passing as recommended.CBLLAGM 2026
- Record Q1 growth, new hospital strategies, and strong margins highlight ongoing expansion.CBLLBank of America Global Healthcare Conference 2026
- Q3 revenue up 48% to $17.2M, 87% gross margin, and $188M+ IPO strengthens growth outlook.CBLLQ3 2024
- 2024 revenue rose 45% to $65.4M, with strong margins and 2025 growth guided at 24–30%.CBLLQ4 2024
Next CeriBell earnings date
Q3 20263 Nov, 2026
CeriBell
Next CeriBell earnings date
Q3 20263 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Ceribell Inc. is a medical technology company specializing in point-of-care electroencephalography (EEG) systems designed to enhance the diagnosis and management of patients with serious neurological conditions. Its flagship product, the Ceribell System, combines portable hardware with artificial intelligence (AI)-powered algorithms to enable rapid detection and continuous monitoring of neurological conditions in acute care settings. The system includes EEG disposable headbands and pocket-sized, battery-operated recorders, facilitating early detection and management of suspected seizure patients. The company is headquartered in Sunnyvale, California, and its shares are listed on the NASDAQ.